Literature DB >> 12401952

Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture.

P Sangchot1, S Sharma, B Chetsawang, J Porter, P Govitrapong, M Ebadi.   

Abstract

One of the defining characteristics of neurodegenerative diseases, including Parkinson's disease, is an abnormal accumulation of iron in the affected brain areas. By using SK-N-SH, a dopaminergic cell line, we have found that iron (100-250 microM FeSO(4)) decreased cell viability, increased lipid peroxidation, and the said effects were blocked by deferoxamine (DFO: 10 microM). Furthermore, DFO, in the absence of iron, enhanced the level of adenosine triphosphate (ATP), but caused chromatin condensation and cell death. Morphological studies revealed that iron (50-100 microM) altered mitochondrial morphology, disrupted nuclear membrane, and translocated alpha-synuclein from perinuclear region into the disrupted nucleus. The results of these studies suggest that DFO is able to block and attenuate iron-mediated oxidative stress. However, in the absence of excess iron, DFO itself may have deleterious effects on the morphology and hence integrity of dopaminergic neurons. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401952     DOI: 10.1159/000065700

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  26 in total

1.  Redox state-dependent aggregation of mitochondria induced by cytochrome c.

Authors:  Victor V Lemeshko
Journal:  Mol Cell Biochem       Date:  2011-09-09       Impact factor: 3.396

2.  Chromatin-Bound Oxidized α-Synuclein Causes Strand Breaks in Neuronal Genomes in in vitro Models of Parkinson's Disease.

Authors:  Velmarini Vasquez; Joy Mitra; Pavana M Hegde; Arvind Pandey; Shiladitya Sengupta; Sankar Mitra; K S Rao; Muralidhar L Hegde
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 3.  Drug Repurposing in Parkinson's Disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

Review 4.  Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.

Authors:  Suzanne M de la Monte
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

5.  The effect of transcatheter injections on cell viability and cytokine release of mononuclear cells.

Authors:  R El Khoury; V Misra; S Sharma; C S Cox; P Walker; J C Grotta; A Gee; S Suzuki; S I Savitz
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-15       Impact factor: 3.825

Review 6.  The role of oxidative stress in Parkinson's disease.

Authors:  Vera Dias; Eunsung Junn; M Maral Mouradian
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

7.  Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons.

Authors:  Patcharee Kooncumchoo; Sushil Sharma; James Porter; Piyarat Govitrapong; Manuchir Ebadi
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

8.  Treatment with the iron chelator, deferoxamine mesylate, alters serum markers of oxidative stress in stroke patients.

Authors:  Magdy Selim
Journal:  Transl Stroke Res       Date:  2009-12-10       Impact factor: 6.829

9.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

Review 10.  The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?

Authors:  Junghee Lee; Jung Hyun Boo; Hoon Ryu
Journal:  Adv Drug Deliv Rev       Date:  2009-08-27       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.